Advertisement

Prodrugs pp 573-651 | Cite as

Prodrug Approaches for Drug Delivery to the Brain

  • Bradley D. Anderson
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

The microvasculature of the human brain consists of approximately 400 miles of capillaries with a surface area of about 100 square feet (Pardridge, 1991). Because the capillary network in the brain is so extensive, Pardridge has suggested that “nearly every neuron is virtually perfused by its own microvessel” (Pardridge, 2002). Yet, despite this extensive surface area and the fact that the blood-brain barrier (BBB) is comprised of a cell monolayer having a thickness of only 200–300 nm, the impermeability of this barrier is widely acknowledged, and methods to circumvent it have been the subject of many reviews (Rapoport, 1976; Rapoport et al., 1979; Fenstermacher and Rapoport, 1984; Neuwelt, 1989; Pardridge, 1991, 1993, 2001; Bradbury, 1992; Drewes and Betz, 1993; Anderson, 1996).

Keywords

Adenosine Deaminase Brain Uptake Cytosine Deaminase Ester Prodrug Brain Delivery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small Je, Herrlinger U, Ourednik V, P. M. Black, Breakefield XO and Snyder EY. Neural Stem Cells Display Extensive Tropism for Pathology in Adult Brain: Evidence from Intracranial Gliomas. Proc Natl Acad Sci USA 2000; 97:12846–12851PubMedGoogle Scholar
  2. Aggarwal SK, Gogu SR, Rangan SRS and Agrawal KC. Synthesis and Biological Evaluation of Prodrugs of Zidovudine. J Med Chem 1990; 33:1505–1510PubMedGoogle Scholar
  3. Aghi M, Kramm CM, Chou TC, Breakefield XO and Chiocca EA. Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene Therapies. J Natl Cancer Inst 1998; 90:370–380PubMedGoogle Scholar
  4. Al-Khalidi UAS and Chaglassian TH. The Species Distribution of Xanthine Oxidase. Biochem J 1965; 97:318–320PubMedGoogle Scholar
  5. Altomare C, Carotti A, Cellamare S, Ferappi M, Cagiano R and Renna G. QSAR Analysis of Chemical and Serum-Catalyzed Hydrolysis of Phenyl Ester Prodrugs of Nipecotic Acid. Int J Pharm 1988; 48:91–102Google Scholar
  6. Anderson BD. Prodrugs for Improved CNS Delivery. Adv Drug Deliv Rev 1996; 19:171–202Google Scholar
  7. Anderson WR, Simpkins JW, Brewster ME and Bodor N. Evidence of the Reestablishment of Copulatory Behavior in Castrated Male Rats with a Brain-Enhanced Estradiol-Chemical Delivery System. Pharmacol Biochem Behav 1986; 27:265–271Google Scholar
  8. Anderson BD, Wygant MB, Xiang T-X, Waugh WA and Stella V. Preformulation Solubility and Kinetic Studies of 2′,3′-Dideoxypurine Nucleosides: Potential Anti-AIDS Agents. Int J Pharm 1988; 45:27–37Google Scholar
  9. Anderson BD, Hoesterey BL, Baker DC and Galinsky RE. Kinetics of DDI in Plasma, Brain, and CSF of Rats after Administration of DDI and an Ester Prodrug of DDI. Ann NY Acad Sci 1990a; 616:472–474Google Scholar
  10. Anderson BD, Hoesterey BL, Baker DC and Galinsky RE. Uptake Kinetics of 2′,3′-Dideoxyinosine into Brain and Cerebrospinal Fluid of Rats: Intravenous Infusion Studies. J Pharmacol Exp Ther 1990b; 253:113–118PubMedGoogle Scholar
  11. Anderson BD, Galinsky RE, Baker DC, Chi S-C, Hoesterey BL, Morgan ME, Murakami K and Mitsuya H. Approaches Toward the Optimization of CNS Uptake of Anti-AIDS Agents. J Control Release 1992; 19:219–230Google Scholar
  12. Anderson BD, Morgan ME and Singhal D. Enhanced Oral Bioavailability of DDI after Administration of 6-CI-DDP, an Adenosine Deaminase-Activated Prodrug, to Chronically Catheterized Rats. Pharm Res 1995; 12:1126–1133PubMedGoogle Scholar
  13. Apiwattanakul N, Sekine T, Chairoungdue A, Kanai Y, Nakajima N, Sophasan S and Endou H. Apiwattanakul N, Sekine T, Chairoungdue A, Kanai Y, Nakajima N, Sophasan S and Endou H. Transport Properties of Nonsteroidal Anti-Inflammatory Drugs by Organic Anion Transporter 1 Expressed in Xenopus Laevis Oocytes Mol Pharmacol 1999; 55:847–854PubMedGoogle Scholar
  14. Badir K, Haj-Yehia A, Vree TB, van der Kleijn E and Bialer M. Pharmacokinetics and Anticonvulsant Activity of Three Monoesteric Prodrugs of Valproic acid. Pharm Res 1991; 8:750–753PubMedGoogle Scholar
  15. Bak A, Gudmundsson OS, Friis GJ, Siahaan TJ and Borchardt RT. Acyloxy-Alkoxy-Based Cyclic Prodrugs of Opioid Peptides: Evaluation of the Chemical and Enzymatic Stability as well as Their Transport Properties Across Caco-2 Cell Monolayers. Pharm Res 1999; 16:24–29PubMedGoogle Scholar
  16. Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, Jacobsen F, Blaney SM, Gress J, Jarosinski P and Poplack DG. Clinical Pharmacology of 2′,3′-Dideoxyinosine in Human Immunodeficiency Virus-Infected Children. J Infect Dis 1992; 165:99–104PubMedGoogle Scholar
  17. Balzarini J, Cooney DA, Dalal M, Kang G-J, Cupp JE, De Clercq E, Broder S and Johns DG. 2′,3′-Dideoxycytidine: Regulation of its Metabolism and Anti-Retroviral Potency by Natural Pyrimidine Nucleosides and by Inhibitors of Pyrimidine Nucleotide Synthesis. Mol Pharmacol 1987; 32:789–806Google Scholar
  18. Balzarini J, Herdewijn P and De Clercq E. Differential Patterns of Intracellular Metabolism of 2′,3′-Didehydro-2′,3′-Dideoxythymidine and 3′-Azido-2′,3′-Dideoxythymidine, Two Potent Anti-Human Immunodeficiency Virus Compounds. J Biol Chem 1989; 264:6127–6133PubMedGoogle Scholar
  19. Barchi JJ, Jr., Marquez VE, Driscoll JS, Ford H, Jr., Mitsuya H, Shirasaka T, Aoki S and Kelley JA. Potential Anti-AIDS Drugs. Lipophilic, Adenosine Deaminase-Activated Prodrugs. J Med Chem 1991; 34:1647–1655PubMedGoogle Scholar
  20. Barnard EA, Borsodi A, Goodman M, Hill R, Hunter JC, Moroder L, Pasternak GW, Portoghese PS, Przewlocki R and Roques BP. What is the Molecular Basis of Opioid Antinociception and How Does this Information Point to New Drug Design? In: Basbaum A, and Besson JM. Towards a New Pharmacotherapy of Pain. New York, John Wiley & Sons Ltd.; 1991:299–315Google Scholar
  21. Bassiri RM and Utiger R. Metabolism and Excretion of Exogenous Thyrotropin-Releasing Hormone in Humans. J Clin Invest 1973; 52:1616–1619PubMedGoogle Scholar
  22. Battaglia G, La Russa M, Bruno V, Arenare L, Ippolito R, Copani A, Bonina F and Nicoletti F. Systemically Administered D-Glucose Conjugates of 7-Chlorokynurenic Acid are Centrally Available and Exert Anticonvulsant Activity in Rodents. Brain Res 2000; 860:149–156PubMedGoogle Scholar
  23. Beaulieu E, Demeule M, Averill-Bates DA and Beliveau R. The Strongest Expression of P-Glycoprotein is in the Blood-Brain Barrier. In: Couraud P-O, and Scherman D. Biology and Physiology of the Blood-Brain Barrier. New York, Plenum Press; 1996:171–174Google Scholar
  24. Beaulieu E, Demeule M, Ghitescu L and Beliveau R. P-Glycoprotein is Strongly Expressed in the Luminal Membranes of the Endothelium of Blood Vessels in the Brain. Biochem J 1997; 326:539–544PubMedGoogle Scholar
  25. Bertler A, Falck B, Owman C and Rosengren E. Localization of Monoaminergic Blood-Brain Barrier Mechanisms. Pharmacol Rev 1966; 18:369–385PubMedGoogle Scholar
  26. Betz AL. Identification of Hypoxanthine Transport and Xanthine Oxidase Activity in Brain Capillaries. J Neurochem 1985; 44:574–579PubMedGoogle Scholar
  27. Betz AL and Goldstein GW. Developmental Changes in Metabolism and Transport Properties of Capillaries Isolated from Rat Brain. J Physiol 1981; 312:365–376PubMedGoogle Scholar
  28. Betz AL, Firth JA and Goldstein GW. Polarity of the Blood-Brain Barrier: Distribution of Enzymes Between the Luminal and Antiluminal Membranes of Brain Capillary Endothelial Cells. Brain Res 1980; 192:17–28PubMedGoogle Scholar
  29. Bickel U and Kang Y-S. Use of Chimeric Peptides in Drug Delivery to the Brain. In: Paulson O, Knudsen GM, and Moos T. Brain Barrier Systems. Alfred Benzon Symposium 45, Copenhagen, Munksgaard; 1999; 478–488Google Scholar
  30. Bickel U, Yoshikawa T, Landaw EM, Faull KF and Pardridge WM. Pharmacological Effects In Vivo in Brain by Vector-Mediated Delivery of Peptides. Proc Natl Acad Sci USA 1993; 90:2618–2622PubMedGoogle Scholar
  31. Bickel U, Kang Y-S and Pardridge WM. In Vivo Cleavability of a Disulfide-Based Chimeric Opioid Peptide in Rat Brain. Bioconjug Chem 1995; 6:211–218PubMedGoogle Scholar
  32. Bickel U, Yoshikawa T and Pardridge WM. Delivery of Peptides and Proteins through the Blood-Brain Barrier. Adv Drug Del Rev 2001; 46:247–279Google Scholar
  33. Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB and Johnson MR. Induction of Thymidine Phosphorylase in Both Irradiated and Shielded, Contralateral Human U87MG Glioma Xenografts: Implications for a Dual Modality Treatment Using Capecitabine and Irradiation. Mol Cancer Ther 2002; 1:1139–1145PubMedGoogle Scholar
  34. Block E and Bennett J. Pharmacological Studies with 5-Fluorocytosine. Med Radiol (Mosk) 1974; 19:476–482Google Scholar
  35. Boado RJ, Li JY, Nagaya M, Zhang C and Pardridge WM. Selective Expression of the Large Neutral Amino Acid Transporter at the Blood-Brain Barrier. Proc Natl Acad Sci USA 1999; 96:12079–12084PubMedGoogle Scholar
  36. Boddy A, Aarons L and Petrak K. Efficiency of Drug Targeting: Steady-State Considerations Using a Three-Compartment Model. Pharm Res 1989; 6:367–372PubMedGoogle Scholar
  37. Bodor N. Drug Targeting and Retrometabolic Drug Design Approaches. Adv Drug Del Rev 1994; 14:157–166Google Scholar
  38. Bodor N. Retrometabolic Approaches to Drug Targeting. NIDA Res Monogr Series 1995; 154:1–26Google Scholar
  39. Bodor N and Brewster M. Problems of Delivery of Drugs to the Brain. Pharmacol Ther 1983; 19:337–386Google Scholar
  40. Bodor N and Prokai L. Molecular Packaging. Peptide Delivery to the Central Nervous System by Sequential Metabolism. In: Taylor MD, and Amidon GL. Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society; 1995; 317–337Google Scholar
  41. Bodor N and Buchwald P. Recent Advances in the Brain Targeting of Neuropharmaceuticals by Chemical Delivery Systems. Adv Drug Del Rev 1999; 36:229–254Google Scholar
  42. Bodor N, Prokai L, Wu W-M, Farag H, Jonalagadda S, Kawamura M and Simpkins J. A Strategy for Delivering Peptides into the Central Nervous System by Sequential Metabolism. Science 1992; 257:1698–1700PubMedGoogle Scholar
  43. Bonina FP, Arenare L, Ippolito R, Boatto G, Battaglia G, Bruno V and De Caprariis P. Synthesis, Pharmacokinetics and Anticonvulsant Activity of 7-Chlorokynurenic Acid Prodrugs. Int J Pharm 2000; 202:79–88PubMedGoogle Scholar
  44. Bonina F, Puglia C, Rimoli MG, Melisi D, Boatto G, Nieddu M, Calignano A, Rana GL and De Caprariis P. Glycosyl Derivatives of Dopamine and L-Dopa as Anti-Parkinson Prodrugs: Synthesis, Pharmacological Activity and In Vitro Stability Studies. J Drug Target 2003; 11:25–36PubMedGoogle Scholar
  45. Bourke RS, West CR, Chheda G and Tower DB. Kinetics of Entry and Distribution of 5-Fluorouracil in Cerebrospinal Fluid and Brain following Intravenous Injection in a Primate. Cancer Res 1973; 33:1735–1746PubMedGoogle Scholar
  46. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P and Brampton MH. Multicentre CRC Phase II Trial of Temozolomide in Recurrent or Progressive High-Grade Glioma. Cancer Chemother Pharmacol 1997; 40:484–488PubMedGoogle Scholar
  47. Bradbury MWB. Physiology and Pharmacology of the Blood-Brain Barrier. Berlin: Springer-Verlag; 1992. 549 pGoogle Scholar
  48. Bradbury A, Finnie M and Smith D. Mechanism of C-Terminal Amide Formation of Pituitary Enzyme. Nature 1982; 298:686–688PubMedGoogle Scholar
  49. Brady TG and O’Donovan CI. A Study of the Tissue Distribution of Adenosine Deaminase in Six Mammal Species. Comp Biochem Physiol 1965; 14:101–120PubMedGoogle Scholar
  50. Bray RC. Molybdenum Iron-Sulfur Flavin Hydrolases and Related Enzymes. In: Boyer PO, Lardy H, and Myrback K. The Enzymes. New York, Academic Press; 1975:533–556Google Scholar
  51. Brecher P, Tercyak A, Gavras H and Chobanian AV. Peptidyl Dipeptidase in Rabbit Brain Microvessels. Biochim Biophys Acta 1978; 526:537–546PubMedGoogle Scholar
  52. Brewster ME and Bodor N. Redox Approaches to Drug Delivery to the Central Nervous System. NIDA Monogr Series 1992; 120:169–201Google Scholar
  53. Brewster ME, Anderson W and Bodor N. Brain, Blood, and Cerebrospinal Fluid Distribution of a Zidovudine Chemical Delivery System in Rabbits. J Pharm Sci 1991; 80:843–846PubMedGoogle Scholar
  54. Brewster ME, Pop E, Braunstein AJ, Pop AC, Druzgala P, Dinculescu A, Anderson W, Elkoussi A and Bodor N. The Effect of Dihydronicotinate N-Substitution on the Brain-Targeting Efficacy of a Zidovudine Chemical Delivery System. Pharm Res 1993; 10:1356–1362PubMedGoogle Scholar
  55. Brewster ME, Raghavan K, Pop E and Bodor N. Enhanced Delivery of Ganciclovir to the Brain through the Use of Redox Targeting. Antimicrob Agents Chemother 1994; 38:817–823PubMedGoogle Scholar
  56. Brewster ME, Anderson WR, Helton DO, Bodor N and Pop E. Dose-Dependent Brain Delivery of Zidovudine through the Use of a Zidovudine Chemical Delivery System. Pharm Res 1995; 12:796–798PubMedGoogle Scholar
  57. Brewster ME, Anderson WR, Webb AI, Pablo LM, Meinsma D, Moreno D, Derendorf H, Bodor N and Pop E. Evaluation of a Brain-Targeting Zidovudine Chemical Delivery System in Dogs. Antimicrob Agents Chemother 1997; 41:122–128PubMedGoogle Scholar
  58. Brightman MW. Morphology of Blood-Brain Interfaces. Exp Eye Res 1977; 25(Suppl.): 1–25PubMedGoogle Scholar
  59. Brightman MW and Reese TS. Junctions between Intimately Apposed Cell Membranes in the Vertebrate Brain. J Cell Biol 1969; 40:648–677PubMedGoogle Scholar
  60. Brightman MW and Tao-Cheng JH. Tight Junctions of Brain Endothelium and Epithelium. In: Pardridge WM. The Blood-Brain Barrier: Cellular and Molecular Biology. New York, Raven Press; 1993:107–125Google Scholar
  61. Brouwers P (1991). Treatment-Related Changes in Pediatric Cognitive Function. Workshop on Neuro-AIDS: Drug Discovery and Development, Portland, MaineGoogle Scholar
  62. Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO and Aboody KS. Intravascular Delivery of Neural Stem Cell Lines to Target Intracranial and Extracranial Tumors of Neural and Non-Neural Origin. Hum Gene Ther 2003; 14:1777–1785PubMedGoogle Scholar
  63. Brownlees J and Williams CH. Peptidase, Peptides, and the Mammalian Blood-Brain Barrier. J Neurochem 1993; 60:793–803PubMedGoogle Scholar
  64. Buchwald P and Bodor N. Quantitative Structure-Metabolism Relationships: Steric and Nonsteric Effects in the Enzymatic Hydrolysis of Noncongener Carboxylic Esters. J Med Chem 1999; 42:5160–5168PubMedGoogle Scholar
  65. Bundgaard H. The Double Prodrug Concept and its Applications. Adv Drug Deliv Rev 1989; 3:39–66Google Scholar
  66. Burns CL, Clair MHS, Frick LW, Spector T, Averett DR, English ML, Holmes TJ, Krenitsky TA and Koszalka GW. Novel 6-Alkoxypurine 2’,3’-Dideoxynucleosides as Inhibitors of the Cytopathic Effect of the Human Immunodeficiency Virus. J Med Chem 1993; 36:378–384PubMedGoogle Scholar
  67. Busby J, W. H., Quackenbush GE, Humm J, Youngblood W and Kizer JS. An Enzyme(s) that Converts Glutaminyl-Peptides into Pyroglutamyl Peptides. Presence in Pituitary, Brain, Adrenal Medulla, and Lymphocytes. J Biol Chem 1982; 262:8532–8536Google Scholar
  68. Butler KM, Husson RN, Balis FM, Brouwers P, Eddy J, El-Amin D, Gress J, Hawkins M, Jarosinski P, Moss H, Poplack D, Santacroce S, Venzon D, Wiener L, Wolters P and Pizzo PA. Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection. N Engl J Med 1991; 324:137–144PubMedCrossRefGoogle Scholar
  69. Carelli V, Liberatore F, Scipione L, Impicciatore M, Barocelli E, Cardellini M and Giorgioni G. New Systems for the Specific Delivery and Sustained Release of Dopamine to the Brain. J Control Release 1996; 42:209–216Google Scholar
  70. Ceresoli-Borroni G, Guidetti P and Schwarz R. Acute and Chronic Changes in Kynurenate Formation following an Intrastriatal Quinolinate Injection in Rats. J Neural Transm 1999; 106:229–242PubMedGoogle Scholar
  71. Chassy BM and Suhadolnik RJ. Adenosine Aminohydrolase. Binding and Hydrolysis of 2-and 6-Substituted Purine Ribonucleosides and 9-Substituted Adenine Nucleosides. J Biol Chem 1967; 242:3655–3658PubMedGoogle Scholar
  72. Chen H, Noble F, Roques BP and Fournié-Zaluski M-C. Long Lasting Antinociceptive Properties of Enkephalin Degrading Enzyme (NEP and APN) Inhibitor Prodrugs. J Med Chem 2001; 44:3523–3530PubMedGoogle Scholar
  73. Chen W, Yang JZ, Andersen R, Nielsen LH and Borchardt RT. Evaluation of the Permeation Characteristics of a Model Peptide Opioid Peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its Cyclic Prodrugs across the Blood-Brain Barrier Using an In Situ Perfused Rat Brain Model. J Pharmacol Exp Ther 2002; 303:849–857PubMedGoogle Scholar
  74. Chen P, Bodor N, Wu W-M and Prokai L. Strategies to Target Kyotorphin Analogues to the Brain. J Med Chem 1998; 41:3773–3781PubMedGoogle Scholar
  75. Chipkin RE. Inhibitors of Enkephalinase: The Next Generation of Analgesics. Drugs Future 1986; 11:593–607Google Scholar
  76. Chu CK, Bhadti VS, Doshi KJ, Etse JT, Gallo JM, Boudinot FD and Schinazi RF. Brain Targeting of Anti-HIV Nucleosides: Synthesis and In Vitro and In Vivo Studies of Dihydropyridine Derivatives of 3′-Azido-2′,3′-Dideoxyuridine and 3′-Azido-3′-Deoxythymidine. J Med Chem 1990a; 33:2188–2192PubMedGoogle Scholar
  77. Chu CK, Ullas GV, Jeong LS, Ahn SK, Doboszewski B, Lin ZX, Beach JW and Schinazi RF. Synthesis and Structure-Activity Relationships of 6-Substituted 2′,3′-Dideoxypurine Nucleosides as Potential Anti-Human Immunodeficiency Virus Agents. J Med Chem 1990b; 33:1553–1561PubMedGoogle Scholar
  78. Cook CS, Karabatsos PJ, Schoenhard GL and Karim A. Species Dependent Esterase Activities for Hydrolysis of an Anti-HIV Prodrug Glycovir and Bioavailability of Active SC-48334. Pharm Res 1995; 12:1158–1164PubMedGoogle Scholar
  79. Cooper AJL. The Role of Glutamine Transaminase K (GTK) in Sulfur and α-Keto Acid Metabolism in the Brain, and in the Possible Bioactivation of Neurotoxicants. Neurochem Int 2004; 44:557–577PubMedGoogle Scholar
  80. Cooper DR, Marrel C, Van de Waterbeemd H, Testa B, Jenner P and Marsden CD. L-Dopa Esters as Potential Prodrugs: Behavioral Activity in Experimental Models of Parkinson’s Disease. J Pharm Pharmacol 1987a; 39:627–635PubMedGoogle Scholar
  81. Cooper DR, Marrel C, Van de Waterbeemd H, Testa B, Jenner P and Marsden CD. L-Dopa Esters as Potential Prodrugs: Effect on Brain Concentration of Dopamine Metabolites in Reserpinized Mice. J Pharm Pharmacol 1987b; 39:809–818PubMedGoogle Scholar
  82. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR. Multidrug-Resistance Gene (P-Glycoprotein) is Expressed by Endothelial Cells at Blood-Brain Barrier Sites. Proc Natl Acad Sci USA 1989; 86:695–698PubMedGoogle Scholar
  83. Crider AM, Tita JD, Wood JD and Hinko CN. Esters of Nipecotic Acid and Iso-Nipecotic Acid as Potential Anticonvulsants. J Pharm Sci 1982; 71:1214–1219PubMedGoogle Scholar
  84. Crider AM, Wood JD, Tschappat KD, Hinko CN and Seibert K. γ-Aminobutyric Acid Uptake Inhibition and Anticonvulsant Activity of Nipecotic Acid Esters. J Pharm Sci 1984; 73:1612–1616PubMedGoogle Scholar
  85. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH and Blaese RM. In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors. Science 1992; 256:1550–1552PubMedGoogle Scholar
  86. Dallaire L, Tremblay L and Beliveau R. Purification and Characterization of Metabolically Active Capillaries of the Blood-Brain Barrier. Biochem J 1991; 276:745–752PubMedGoogle Scholar
  87. de Varebeke PJ, Cavalier R, David-Ramacle M and Youdim MBH. Formation of the Neurotransmitter Glycine from the Anticonvulsant Milacemide is Mediated by Brain Monoamine Oxidase B. J Neurochem 1988; 50:1011–1016Google Scholar
  88. DeGraw RT and Anderson BD. Enhanced Oral Bioavailability of 2′-β-Fluoro-2′,3′-Dideoxyadenosine (F-ddA) through Local Inhibition of Intestinal Adenosine Deaminase. Pharm Res 2001; 18:1270–1276PubMedGoogle Scholar
  89. Deguchi Y and Morimoto K. Application of an In Vivo Brain Microdialysis Technique to Studies of Drug Transport across the Blood-Brain Barrier. Current Drug Metab 2001; 2:411–423Google Scholar
  90. Deguchi Y, Inabe K, Tomiuasu K, Nozawa K, Yamada S and Kimura R. Study on Brain Interstitial Fluid Distribution and Blood-Brain Barrier Transport of Baclofen in Rats by Microdialysis. Pharm Res 1995; 12:1838–1844PubMedGoogle Scholar
  91. Deguchi Y, Hayashi H, Fujii S, Naito T, Yokoyama Y, Yamada S and Kimura R. Improved Brain Delivery of a Nonsteroidal Anti-Inflammatory Drug with a Synthetic Glyceride Ester: A Preliminary Attempt at a CNS Drug Delivery System for the Therapy of Alzheimer’s Disease. J Drug Target 2000; 8:371–381PubMedGoogle Scholar
  92. Denny BJ, Wheelhouse RT, Stevens MFG, Tsang LLH and Slack JA. NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA. Biochemistry 1994; 33:9045–9051PubMedGoogle Scholar
  93. DePierre JW and Morgenstern R. Comparison of the Distribution of Microsomal and Cytosolic Glutathione S-Transferase Activities in Different Organs of the Rat. Biochem Pharmacol 1983; 32:721–723PubMedGoogle Scholar
  94. Dixon M and Webb E. Enzymes. New York, Academic; 1979. 1116 pGoogle Scholar
  95. Djuricic BM and Mrsulja BB. Enzymic Activity of the Brain: Microvessels vs. Total Forebrain Homogenate. Brain Res 1977; 138:561–564PubMedGoogle Scholar
  96. Doheny MH, Shigeru N and Patsalos PN. A Microdialysis Study of Glycinamide, Glycine and Other Amino Acid Neurotransmitters in Rat Frontal Cortex and Hippocampus after the Administration of Milacemide, a Glycine Pro-Drug. Naunyn-Schmiedeberg’s Arch Pharmacol 1996; 354:157–163Google Scholar
  97. Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirshowitz EA, Crystal R, Weichselbaum R, Kufe DW and Fine HA. In Vivo Replication-Deficient Adenovirus Vector-Mediated Transduction of the Cytosine Deaminase Gene Sensitizes Glioma Cells to 5-Fluorocytosine. Hum Gene Ther 1996; 7:713–720PubMedGoogle Scholar
  98. Drewes LR and Betz AL, Eds. Drewes LR and Betz AL, Eds. Frontiers in Cerebral Vascular Biology: Transport and Its Regulation Advances in Experimental Medicine and Biology New York, Plenum Press; 1993. 295 pGoogle Scholar
  99. Driscoll JS. AIDS: Adenosine Deaminase-Activated Prodrugs Designed for the Treatment of Human Immunodeficiency Virus in the Central Nervous System. In: Torrence PF. Biomedical Chemistry: Applying Chemical Principles to the Understanding and Treatment of Disease. New York: John Wiley & Sons, Inc.; 2000:99–114Google Scholar
  100. Driscoll JS, Siddiqui MA, Ford J, H., Kelley JA, Roth JS, Mitsuya H, Tanaka M and Marquez VE. Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 3. 6-Amino Prodrugs of 2′-β-Fluoro-2′,3′-Dideoxyinosine. J Med Chem 1996; 39:1619–1625PubMedGoogle Scholar
  101. Durrer A, Walther B, Racciatti A, Boss G and Testa B. Structure-Metabolism Relationships in the Hydrolysis of Nicotinate Esters by Rat Liver and Brain Subcellular Fractions. Pharm Res 1991; 8:832–839PubMedGoogle Scholar
  102. Dykstra KH, Arya A, Arriola DM, Bungay PM, Morrison PF and Dedrick RL. Microdialysis Study of Zidovudine (AZT) Transport in Rat Brain. J Pharmacol Exp Ther 1993; 267:1227–1236PubMedGoogle Scholar
  103. Eraly SA, Hamilton BA and Nigam SK. Organic Anion and Cation Transporters Occur in Pairs of Similar and Similarly Expressed Genes. Biochem Biophys Res Commun 2003; 300:333–342PubMedGoogle Scholar
  104. Erb C, Seidel A, Frank H, Platt KL, Oesch F and Klein J. Formation of N-Methylnicotinamide in the Brain from a Dihydroyridine-Type Prodrug. Biochem Pharm 1999; 57:681–684PubMedGoogle Scholar
  105. Estonius M, Forsberg L, Danielsson O, Weinander R, Kelner MJ and Morgenstern R. Distribution of Microsomal Glutathione Transferase 1 in Mammalian Tissues. A Predominant Alternate First Exon in Human Tissues. Eur J Biochem 1999; 260:409–413PubMedGoogle Scholar
  106. Ezzeddine ZD, Martuza RL, Platika D, short MP, Malick A, Choi B and Breakefield XO. Selective Killing of Glioma Cells in Culture and In Vivo by Retrovirus Transfer of the Herpes Virus Thymidine Kinase Gene. Nature Biol 1991; 3:608–614Google Scholar
  107. Faden AI, Vink R and McIntosh TK. Thyrotropin-Releasing Hormone and Central Nervous System Trauma. Ann N Y Acad Sci 1989; 553:380–384PubMedGoogle Scholar
  108. Farrell CL and Pardridge WM. Blood-Brain Barrier Glucose Transporter is Asymmetrically Distributed on Brain Capillary Endothelial Lumenal and Ablumenal Membranes: An Electron Microscopic Immunogold Study. Proc Natl Acad Sci 1991; 88:5779–5783PubMedGoogle Scholar
  109. Feener EP, Shen W-C and Ryser HJP. Cleavage of Disulfide Bonds in Endocytosed Macromolecules. J Biol Chem 1990; 265:18780–18785PubMedGoogle Scholar
  110. Fenstermacher JD and Rapoport SI. Blood-Brain Barrier. In: Renkin EM, and Michel CC. Handbook of Physiology Section 2: The Cardiovascular System Vol IV: Microcirculation. Washington, D.C., American Physiological Society; 1984:969–1000Google Scholar
  111. Fernandez C, Nieto O, Fontenla JA, Rivas E, de Ceballos ML and Fernandez-Mayoralas A. Synthesis of Glycosyl Derivatives as Dopamine Prodrugs: Interaction with Glucose Carrier GLUT-1. Org Biomol Chem 2003; 1:767–771PubMedGoogle Scholar
  112. Finberg JPM and Youdim MBH. Monoamine Oxidases. In: Lajtha A. Handbook of Neurochemistry. New York, Plenum Press; 1983:293–313Google Scholar
  113. Fischer W and Spiess J. Identification of a Mammalian Glutaminyl Cyclase Converting Glutaminyl into Pyroglutaminyl Peptides. Proc Natl Acad Sci USA 1987; 84:3628–3632PubMedGoogle Scholar
  114. Flaherty P, Castagnoli K, Wang Y-X and Castagnoli J, N. Synthesis and Selective Monoamine Oxidase-B-Inhibiting Properties of 1-Methyl-1,2,3,6-Tetrahydropyrid-4-yl Carbamate Derivatives: Potential Prodrugs of (R)-and (S)-Nordeprenyl. J Med Chem 1996; 39:4756–4761PubMedGoogle Scholar
  115. Ford H, Jr., Siddiqui MA, Driscoll JS, Marquez VE, Kelley JA, Mitsuya H and Shirasaka T. Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 2. 6-Halo and 6-Alkoxy Prodrugs of 2′-β-Fluoro-2′,3′-Dideoxyinosine. J Med Chem 1995; 38:1189–1195PubMedGoogle Scholar
  116. Fournie-Zaluski M-C, Coric P, Turcaud S, Bruetschy L, Lucas E, Noble F and Roques BP. Potent and Systemically Active Aminopeptidase N Inhibitors Designed from Active-Site Investigation. J Med Chem 1992a; 35:1259–1266PubMedGoogle Scholar
  117. Fournie-Zaluski M-C, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R and Roques BP. “Mixed Inhibitor-Prodrug” as a New Approach toward Systemically Active Inhibitors of Enkephalin-Degrading Enzymes. J Med Chem 1992b; 35:2473–2481PubMedGoogle Scholar
  118. Frey HH, Popp C and Loscher W. Influence of Inhibitors of the High Affinity GABA Uptake on Seizure Thresholds in Mice. Neuropharmacol 1979; 18:581–590Google Scholar
  119. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B and Starzyk RM. Anti-Transferrin Receptor Antibody and Antibody-Drug Conjugate across the Blood-Brain Barrier. Proc Natl Acad Sci USA 1991; 88:4771–4775PubMedGoogle Scholar
  120. Furman PA, Fyfe JA, Clair MHS, Weinhold K, Rideout JL, Freeman GA, Nusinoff Lehrman S, Bolognesi DP, Broder S, Mitsuya H and Barry DW. Phosphorylation of 3′-Azido-3′-Deoyxthymidine and Selective Interaction of the 5′-Triphosphate with Human Immunodeficiency Virus Reverse Transcriptase. Proc Natl Acad Sci USA 1986; 83:8333–8337PubMedGoogle Scholar
  121. Galinsky RE, Hoesterey BL and Anderson BD. Brain and Cerebrospinal Fluid Uptake of Zidovudine (AZT) in Rats after Intravenous Injection. Life Sci 1990; 47:781–788PubMedGoogle Scholar
  122. Galinsky RE, Flaharty KK, Hoesterey BL and Anderson BD. Probenecid Enhances Central Nervous System Uptake of 2′,3′-Dideoxyinosine by Inhibiting Cerebrospinal Fluid Efflux. J Pharmacol Exp Ther 1991; 257:972–978PubMedGoogle Scholar
  123. Gallo JM, Etse JT, Doshi KJ, Boudinot FD and Chu CK. Hybrid Pharmacokinetic Models to Describe Anti-HIV Nucleoside Brain Disposition following Parent and Prodrug Administration in Mice. Pharm Res 1991; 8:247–253PubMedGoogle Scholar
  124. Gao W-Y, Shirasaka T, Johns DG, Broder S and Mitsuya H. Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral Blood Mononuclear Cells. J Clin Invest 1993; 91:2326–2333PubMedGoogle Scholar
  125. Gao W-Y, Agbaria R, Driscoll JS and Mitsuya H. Divergent Anti-Human Immunodeficiency Virus Activity and Anabolic Phosphorylation of 2′,3′-Dideoxynucleoside Analogs in Resting and Activated Human Cells. J Biol Chem 1994; 269:12633–12638PubMedGoogle Scholar
  126. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A and Meier PJ. Organic Anion-Transporting Polypeptides Mediate Transport of Opioid Peptides across Blood-Brain Barrier. J Pharmacol Exp Ther 2000; 294:73–79PubMedGoogle Scholar
  127. Ge K, Xu L, Zheng Z, Xu D, Sun L and Liu X. Transduction of Cytosine Deaminase Gene Makes Rat Glioma Cells Highly Sensitive to 5-Fluorocytosine. Int J Cancer 1997; 71:675–679PubMedGoogle Scholar
  128. Ghersi-Egea JF, Leninger-Muller B, Suleman G, Siest G and Minn A. Localization of Drug-Metabolizing Enzyme Activities to Blood-Brain Interfaces and Circumventricular Organs. J Neurochem 1994; 62:1089–1096PubMedCrossRefGoogle Scholar
  129. Ghersi-Egea J-F, Minn A and Siest G. A New Aspect of the Protective Functions of the Blood-Brain Barrier: Activities of Four Drug-Metabolizing Enzymes in Isolated Rat Brain Microvessels. Life Sci 1988; 42:2515–2523PubMedGoogle Scholar
  130. Gohlke P, Urbach H, Scholkens B and Unger T. Inhibition of Converting Enzyme in the Cerebrospinal Fluid of Rats after Oral Treatment with Converting Enzyme Inhibitors. J Pharmacol Exp Ther 1989; 249:609–616PubMedGoogle Scholar
  131. Gomori G. The Distribution of Phosphatase in Normal Organs and Tissues. J Cell Comp Physiol 1941; 17:71–83Google Scholar
  132. Gramsbergen JBP, Hodgkins PS, Rassoulpour A, Turski WA, Guidetti P and Schwarcz R. Brain-Specific Modulation of Kynurenic Acid Synthesis in the Rat. J Neurochem 1997; 69:290–298PubMedCrossRefGoogle Scholar
  133. Greig NH. Drug Delivery to the Brain by Blood-Brain Barrier Circumvention and Drug Modification. In: Neuwelt EA. Implications of the Blood-Brain Barrier and Its Manipulation. New York, Plenum; 1989:311–367Google Scholar
  134. Greig NH, Daly EM, Sweeney DJ and Rapoport SI. Pharmacokinetics of Chlorambucil-Tertiary Butyl Ester, a Lipophilic Chlorambucil Derivative that Achieves and Maintains High Concentrations in Brain. Cancer Chemother Pharmacol 1990a; 25:311–319PubMedGoogle Scholar
  135. Greig NH, Soncrant TT, Shetty HU, Momma S and Smith QR. Brain Uptakes and Anticancer Activities of Vincristine and Vinblastine are Restricted by their Low Cerebrovascular Permeability and Binding to Plasma Constituents in Rat. Cancer Chemother Pharmacol 1990b; 26:263–268PubMedGoogle Scholar
  136. Groothuis DR and Levy RM. The Entry of Antiviral and Antiretroviral Drugs into the Central Nervous System. J NeuroVirology 1997; 3:387–400CrossRefGoogle Scholar
  137. Guidetti P, Okuno E and Schwarcz R. Characterization of Rat Brain Kynurenine Amino-Transferases I and II. J Neurosci Res 2000; 50:457–465Google Scholar
  138. Gunther W, Pawlak E, Damasceno R, Arnold H and Terzis AJ. Temozolomide Induces Apoptosis and Senescence in Glioma Cells Cultured as Multicellular Spheroids. Br J Cancer 2003; 88:463–469PubMedGoogle Scholar
  139. Guyon A, Roques BP, Guyon F, Foucault A, Perdrisot R, Swerts JP and Schwartz JC. Enkephalin Degradation in Mouse Brain Studied by a New HPLC Method: Further Evidence for the Involvement of a Carboxydipeptidase. Life Sci 1979; 25:1605–1612PubMedGoogle Scholar
  140. Handelmann GE, Nevins ME, Mueller LL, Arnolde SM and Cordi AA. Milacemide, a Glycine Prodrug, Enhances Performance of Learning Tasks in Normal and Amnestic Rodents. Pharmacol Biochem Behav 1989; 34:823–828PubMedGoogle Scholar
  141. Hao Z, Cooney DA, Hartman NR, Perno CF, Fridland A, DeVico AL, Sarngadharan MG, Broder S and Johns DG. Factors Determining the Activity of 2′,3′-Dideoxynucleosides in Suppressing Human Immunodeficiency Virus In Vitro. Mol Pharmacol 1988; 34:431–435PubMedGoogle Scholar
  142. Hao Z, Cooney DA, Farquhar D, Perno CF, Zhang K, Masood R, Wilson Y, Hartman NR, Balzarini J and Johns DG. Potent DNA Chain Termination Activity and Selective Inhibition of Human Immunodeficiency Virus Reverse Transcriptase by 2′,3′-Dideoxyuridine-5′-Triphosphate. Mol Pharmacol 1990; 37:157–163PubMedGoogle Scholar
  143. Hardebo JE and Owman C. Barrier Mechanisms for Neurotransmitter Monoamines and their Precursors at the Blood-Brain Barrier. Ann Neurol 1979; 8:1–11Google Scholar
  144. Hardebo JE and Owman C. Characterization of the In Vitro Uptake of Monoamines into Brain Microvessels. Acta Physiol Scand 1980; 108:223–229PubMedGoogle Scholar
  145. Hardebo JE, Falck B, Owman C and Rosengren E. Studies on the Enzymatic Blood-Brain Barrier: Quantitative Measurements of DOPA Decarboxylase in the Wall of Microvessels as Related to the Parenchyma in Various CNS Regions. Acta Physiol Scand 1979; 105:453–460PubMedGoogle Scholar
  146. Hardebo JE, Emson PC, Falck B, Owman C and Rosengren E. Enzymes Related to Monoamine Transmitter Metabolism in Brain Microvessels. J Neurochem 1980; 35:1388–1393PubMedGoogle Scholar
  147. Hasegawa M, Kusuhara H, Endou H and Sugiyama Y. Contribution of Arganic anion Transporters to the Renal Uptake of Anionic Compounds and Nucleoside Derivatives in Rat. J Pharmacol Exp Ther 2003; 305:1087–1097PubMedGoogle Scholar
  148. Hawkins ME, Mitsuya H, McCully CM, Godwin KS, Murakami K, Poplack DG and Balis FM. Pharmacokinetics of Dideoxypurine Nucleoside Analogs in Plasma and Cerebrospinal Fluid of Rhesus Monkeys. Antimicrob Agents Chemother 1995; 39:1259–1264PubMedGoogle Scholar
  149. Hedaya MA and Sawchuk RJ. Effect of Probenecid on the Renal and Nonrenal Clearances of Zidovudine and its Distribution into Cerebrospinal Fluid in the Rabbit. J Pharm Sci 1989; 78:716–722PubMedGoogle Scholar
  150. Henin Y, Gouyette C, Schwartz O, Debouzy J-C, Neumann J-M and Huynh-Dinh T. Lipophilic Glycosyl Phosphotriester Derivatives of AZT: Synthesis, NMR Transmembrane Transport Study, and Antiviral Activity. J Med Chem 1991; 34:1830–1837PubMedGoogle Scholar
  151. Hersh LB, Aboukhair N and Watson S. Immunohistochemical Localization of Aminopeptidase M in Rat Brain and Periphery: Relationship of Enzyme Localization and Enkephalin Metabolism. Peptides 1987; 8:523–532PubMedGoogle Scholar
  152. Hesse GW, Jacob JN and Shashoua VE. Uptake in Brain and Neurophysiological Activity of Two Lipid Esters of γ-Aminobutyric Acid. Neuropharmacol 1988; 27:637–640Google Scholar
  153. Hinko CN, Seibert K and Crider AM. Anticonvulsant Activity of the Nipecotic Acid Ester, (+/−)-m-Nitrophenyl-3-Piperidine Carboxylate. Neuropharmacology 1984; 23:1009–1014PubMedGoogle Scholar
  154. Hinko CN, Crider AM and Wood JD. A Comparison of Prodrug Esters of Nipecotic Acid. Neuropharmacol 1988; 27:475–483Google Scholar
  155. Ho DHW, Pincus C, Carter CJ, Benjamin RS, Freireich EJ and Bodey S, G. P. Distribution and Inhibition of Adenosine Deaminase in Tissues of Man, Rat, and Mouse. Cancer Treat Rep 1980; 64:629–633PubMedGoogle Scholar
  156. Hoesterey BL, Galinsky RE and Anderson BD. Dose Dependence in the Plasma Pharmacokinetics and Uptake Kinetics of 2′,3′-Dideoxyinosine (ddI) into Brain and CSF of Rats. Drug Metab Disp 1991; 19:907–912Google Scholar
  157. Hokari M, Wu H-Q, Schwarcz R and Smith QR. Facilitated Brain Uptake of 4-Chlorokynurenine and Conversion to 7-Chlorokynurenic Acid. NeuroReport 1996; 8:15–18PubMedGoogle Scholar
  158. Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF and Miller DW. Expression of Multidrug Resistance-Associated Protein (MRP) in Brain Microvessel Endothelial Cells. Biochem Biophys Res Commun 1998; 243:816–820PubMedGoogle Scholar
  159. Husain I and Tate SS. Formation of the COOH-Terminal Amide Group of Thyrotropin-Releasing Factor. FEBS Lett 1983; 152:277–281PubMedGoogle Scholar
  160. Inomata K, Yoshioka T, Nasu F and Mayahara H. Ultracytochemical Studies of Capillary Endothelial Cells in the Rat Central Nervous System. Acta Anat 1984; 118:243–248PubMedGoogle Scholar
  161. Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, Oldfield EH, Johns DG and Blaese RM. Mechanism of “Bystander Effect” Killing in the Herpes Simplex Thymidine Kinase Gene Therapy Model of Cancer. Gene Ther 1997; 4:244–251PubMedGoogle Scholar
  162. Ishikura T, Senou T, Ishihara H, Kato T and Ito T. Drug Delivery to the Brain. DOPA Prodrugs Based on a Ring-Closure Reaction to Quaternary Thiazolium Compounds. Int J Pharm 1995; 116:51–63Google Scholar
  163. Itoh Y, Ogasawara T, Mushiori A, Yamazaki A, Ukai Y and Kimura KJ. Effect of NS-3, a Thyrotropin-Releasing Hormone Analog, on In Vivo Acetylcholine Release in Rat Brain: Regional Differences and its Sites of Action. J Pharmacol Exp Ther 1994; 271:884–890PubMedGoogle Scholar
  164. Izquierdo M, Cortes M, De Felipe P, Martin V, Diezguerra J, Talavera A and Perez-Higueras A. Long-Term Rat Survival after Malignant Brain Tumour Regression by Retroviral Gene Therapy. Gene Ther 1995; 2:66–69PubMedGoogle Scholar
  165. Jackson I. Controversies in TRH Biosynthesis and Strategies towards the Identification of a TRH Precursor. Ann NY Acad Sci 1989; 553:71–75Google Scholar
  166. Jacob JN, Shashoua VE, Campbell A and Baldessarini RJ. γ-Aminobutyric Acid Esters. 2. Synthesis, Brain Uptake, and Pharmacological Properties of Lipid Esters of γ-Aminobutyric Acid. J Med Chem 1985; 28:106–110PubMedGoogle Scholar
  167. Jacob JN, Hesse GW and Shashoua VE. Synthesis, Brain Uptake, and Pharmacological Properties of a Glyceryl Lipid Containing GABA and the GABA-T Inhibitor γ-vinyl-GABA. J Med Chem 1990; 33:733–736PubMedGoogle Scholar
  168. Jacobs AH, Winkeler A, Dittmar C, Vollmar S, Wienhard K, Reszka R, Voges J and Heiss W-D. Positron-Emission Tomography Monitoring of Anti-Glioblastoma HSV-1-TK Gene Therapy. Gene Ther Reg 2002; 2:49–57Google Scholar
  169. Janinis J, Efstathiou E, Panopoulos C, Samantas E, Aravantinos G, Christodoulou C and Skarlos D. Phase II Study of Temozolomide in Patients with Relapsing High Grade Glioma and Poor Performance Status. Med Oncol 2000; 17:106–110PubMedGoogle Scholar
  170. Jefferies AA, Brandon MR, Hunt SV, Williams AF, Gatter KC and Mason DY. Transferrin Receptor on Endothelium of Brain Capillary. Nature 1984; 312:162–163PubMedGoogle Scholar
  171. Jette L and Beliveau R. P-Glycoprotein is Strongly Expressed in Brain Capillaries. In: Drewes LR, and Betz AL. Frontiers in Cerebral Vascular Biology: Transport and Its Regulation. New York, Plenum Press; 1993:121–125Google Scholar
  172. Johnson M and Fridland A. Phosphorylation of 2′,3′-Dideoxyinosine by Cytosolic 5′-Nucleotidase of Human Lymphoid Cells. Mol Pharmacol 1989; 36:291–295PubMedGoogle Scholar
  173. Johnson MD and Anderson BD. Localization of Purine Metabolizing Enzymes in Bovine Brain Microvessel Endothelial Cells: An Enzymatic Blood-Brain Barrier for Dideoxynucleosides? Pharm Res 1996; 13:1881–1886PubMedGoogle Scholar
  174. Johnson MD and Anderson BD. Use of Cultured Cerebral Capillary Endothelial Cells in Modeling the Central Nervous System Availability of 2′,3′-Dideoxyinosine. J Pharm Sci 2000; 89:322–335PubMedGoogle Scholar
  175. Johnson MA, Ahluwalia G, Connelly MC, Cooney DA, Broder S, Johns DG and Fridland A. Metabolic Pathways for the Activation of the Antiretroviral Agent 2′,3′-Dideoxyadenosine in Human Lymphoid Cells. J Biol Chem 1988; 263:15354–15357PubMedGoogle Scholar
  176. Jones RJ and Bischofberger N. Minireview: Nucleotide Prodrugs. Antiviral Res 1995; 27:1–17PubMedGoogle Scholar
  177. Jones DB, Rustgi VK, Kornhauser DM, Woods A, Quinn R, Hoofnagle JH and Jones EA. The Disposition of 6-Deoxyacyclovir, a Xanthine Oxidase-Activated Prodrug of Acyclovir, in the Isolated Perfused Rat Liver. Hepatology 1987; 7:345–348PubMedGoogle Scholar
  178. Kalaria RN and Harik SI. Blood-Brain Barrier Monoamine Oxidase: Enzyme Characterization in Cerebral Microvessels and Other Tissues from Six Mammalian Species, including Humans. J Neurochem 1987; 49:856–864PubMedGoogle Scholar
  179. Kawaguchi T, Ishikawa K, Seki T and Juni K. Ester Prodrugs of Zidovudine. J Pharm Sci 1990; 79:531–533PubMedGoogle Scholar
  180. Kikuchi R, Kusuhara H, Sugiyama D and Sugiyama Y. Contribution of Organic Anion Transporter 3 (Slc22a8) to the Elimination of p-Aminohippuric Acid and Benzylpenicillin across the Blood-Brain Barrier. J Pharmacol Exp Ther 2003; 306:51–58PubMedGoogle Scholar
  181. Killian DM and Chikhale PJ. A Bioreversible Prodrug Approach Designed to Shift Mechanism of Brain Uptake for Amino-Acid-Containing Anticancer Agents. J Neurochem 2000; 76:966–974Google Scholar
  182. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM and Wilkinson GR. The Drug Transporter P-Glycoprotein Limits Oral Absorption and Brain Entry of HIV-1 Protease Inhibitors. J Clin Invest 1998; 101:289–294PubMedGoogle Scholar
  183. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mlkhtari K, Diquet B, Salzmann JL and Philippon J. A Phase I/II Study of Herpes Simplex Virus Type I Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma. Hum Gene Ther 1998; 9:2595–2604PubMedGoogle Scholar
  184. Krause M, Stark H and Schunack W. Azomethine Prodrugs of (R)-α-Methylhistamine, a Highly Potent and Selective Histamine H3-Receptor Agonist. Curr Med Chem 2001; 8:1329–1340PubMedGoogle Scholar
  185. Krenitsky TA, Hall WW, de Miranda P, Beauchamp LM, Schaeffer HJ and Whiteman PD. 6-Deoxyacyclovir: A Xanthine Oxidase-Activated Prodrug of Acyclovir. Proc Natl Acad Sci USA 1984; 81:3209–3213PubMedGoogle Scholar
  186. Krisch K. Carboxylic Ester Hydrolases. In: Boyer P. The Enzymes. London, Academic; 1971:43–69Google Scholar
  187. Krogsgaard-Larsen P and Johnston GAR. Inhibition of GABA Uptake in Rat Brain Slices by Nipecotic Acid, Various Isoxazoles and Related Compounds. J Neurochem 1975; 25:797–802PubMedGoogle Scholar
  188. Kusuhara H and Sugiyama Y. Role of Transporters in the Tissue-Selective Distribution and Elimination of Drugs: Transporters in the Liver, Small Intestine, Brain and Kidney. J Control Rel 2002; 78:43–54Google Scholar
  189. Kusuhara H, Suzuki H, Naito M, Tsuruo T and Sugiyama Y. Characterization of Efflux Transport of Organic Anions in a Mouse Brain Capillary Endothelial Cell Line. J Pharmacol Exp Ther 1998; 285:1260–1265PubMedGoogle Scholar
  190. Lai FM, Berkowitz B and Spector S. Influence of Age on Brain Vascular and Cardiovascular Monoamine Oxidase Activty in the Tat. Life Sci 1978; 22:2051–2056PubMedGoogle Scholar
  191. Lambert DM. Rationale and Applications of Lipids as Prodrug Carriers. Eur J Pharm Sci 2000; 11Suppl. 2:S15–S27PubMedGoogle Scholar
  192. Lambert SM, Mergen F, Poupaert JH and Dumont P. Analgesic Potency of S-Acetylthiorphan after Intravenous Administration to Mice. Eur J Pharmacol 1993; 243:129–134PubMedGoogle Scholar
  193. Lampe T, Norris J, Risse S, Owens-Williams E and Keenan T. Basic Mechanisms, Diagnosis and Therapeutic Strategies. In: Iqbal K, McLachlan DRC, Winbald B, and Wisniewski HM. Alzheimer’s Disease. New York, John Wiley & Sons, Ltd.; 1991:643Google Scholar
  194. Lecomte JM, Costentin J, Vlaiculescu A, Chaillet P, Marcais-Collado H, Llorens-Cortes C, Leboyer M and Schwartz J-C. Pharmacological Properties of Acetorphan, a Parenterally Active “Enkephalinase” Inhibitor. J Pharmacol Exp Ther 1986; 237:937–944PubMedGoogle Scholar
  195. Lee S-C and Schwarcz R. Excitotoxic Injury Stimulates Pro-Drug-Induced 7-Chlorokynurenate Formation in the Rat Striatum In Vivo. Neurosci Lett 2001; 304:185–188PubMedGoogle Scholar
  196. Lee G, Dallas S, Hong M and Bendayan R. Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations. Pharmacol Rev 2001; 53:569–596PubMedGoogle Scholar
  197. Leeson PD and Iversen LL. The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential. J Med Chem 1994; 37:4053–4067PubMedGoogle Scholar
  198. Lefebvre I, Perigaud C, Pompon A, Aubertin A-M, Girarder J-L, Kirn A, Gosselin G and Imbach J-L. Mononucleoside Phosphotriester Derivatives with S-Acyl-2-Thioethyl Bioconvertible Phosphate-Protecting Groups: Intracellular Delivery of 3′-Azido-2′,3′-Dideoxythymidine 5′-Monophosphate. J Med Chem 1995; 38:3941–3950PubMedGoogle Scholar
  199. Leisen C, Langguth P, Herbert B, Dressler C, Koggel A and Spahn-Langguth H. Lipophilicities of Baclofen Ester Prodrugs Correlate with Affinities to the ATP-Dependent Efflux Pump P-Glycoprotein: Relevance for their Permeation across the Blood-Brain Barrier. Pharm Res 2003; 20:772–778PubMedGoogle Scholar
  200. Lieb WR and Stein WD. Simple Diffusion across the Membrane Bilayer. In: Stein WD. Transport and Diffusion across Cell Membranes. Orlando, Florida, Academic Press, Inc.; 1986:69–112Google Scholar
  201. Lindsay S, Liu TH, Xu JA, Marshall PA, Thompson JK, Parks DA, Freeman BA, Hsu CY and Beckman JS. Role of Xanthine Dehydrogenase and Oxidase in Focal Cerebral Ischemic Injury to Rat. Am J Physiol 1991; 261:H2051–2057PubMedGoogle Scholar
  202. Little R, Bailey D, Brewster ME, Estes KS, Clemmons RM, Saab A and Bodor N. Improved Delivery through Biological Membranes. XXXIII. Brain-Enhanced Delivery of Azidothymidine (AZT). J Biopharm Sci 1990; 1:1–18Google Scholar
  203. Lodge D, Johansen GAR, Curtis DR and Brand SJ. Effects of Areca Nut Constituents Arecaidine and Guvacine on the Action of GABA in the Cat Central Nervous system. Brain Res 1977; 136:513–522PubMedGoogle Scholar
  204. Lodish HF and Kong N. The Secretory Pathway is Normal in Dithiothreitol-Treated Cells, but Disulfide-Bonded Proteins are Reduced and Reversibly Retained in the Endoplasmic Reticulum. J Biol Chem 1993; 268:20598–20605PubMedGoogle Scholar
  205. Lupia RH, Ferencz N, Aggarwal S, Agrawal KC and Lertora JJL (1991). Pharmacokinetics and Brain Penetration of Zidovudine Derived from Two Novel Prodrugs. AIDS Clinical Trials Group Meeting, July 1991, Bethesda, MDGoogle Scholar
  206. Lupia RH, Ferencz N, Lertora JJL, Aggarwal SK, George WJ and Agrawal KC. Comparative Pharmacokinetics of Two Prodrugs of Zidovudine in Rabbits: Enhanced Levels of Zidovudine in Brain Tissue. Antimicrob Agents Chemother 1993; 37:818–824PubMedGoogle Scholar
  207. Malfroy B, Swerts JP, Guyon A, Roques BP and Schwartz J-C. High Affinity Enkephalin-Degrading Peptidase in Brain is Increased after Morphine. Nature (Lond) 1978; 276:523–526Google Scholar
  208. Manouilov KK, Manouilova LS, Boudinot FD, Schinazi RF and Chu CK. Biotransformation and Pharmacokinetics of Prodrug 9-(β-D-1,3-Dioxolan-4-yl)-2-Aminopurine and its Antiviral Metabolite 9-((β-D-1,3-Dioxolan-4-yl)Guanine in Mice. Antiviral Res 1997; 35:187–193PubMedGoogle Scholar
  209. Marquez VE, Tseng CK-H, Kelley JA, Mitsuya H, Broder S, Roth JS and Driscoll JS. 2′,3′-Dideoxy-2′-Fluoro-Ara-A. An Acid-Stable Purine Nucleoside Active Against Human Immunodeficiency Virus (HIV). Biochem Pharmacol 1987; 36:2719–2722PubMedGoogle Scholar
  210. Marquez VE, Tseng CK-H, Mitsuya H, Aoki S, Kelley JA, Ford J, H., Roth JS, Broder S, Johns DG and Driscoll JS. Acid-Stable 2′-Fluoro Purine Dideoxynucleosides as Active Agents against HIV. J Med Chem 1990; 33:978–985PubMedGoogle Scholar
  211. Minagawa T, Kohno Y, Suwa T and Tsuji A. Species Differences in Hydrolysis of Isocarbacyclin Methyl Ester (TEI-9090) by Blood Esterases. Biochem Pharmacol 1995; 49:1361–1365PubMedGoogle Scholar
  212. Minn A, Ghersi-Egea J-F, Perrin R, Leininger B and Siest G. Drug Metabolizing Enzymes in the Brain and Cerebral Microvessels. Brain Res Rev 1991; 16:65–82PubMedGoogle Scholar
  213. Mistry G and Drummond GI. Adenosine Metabolism in Microvessels from Heart and Brain. J Mol Cell Cardiol 1986; 18:13–22PubMedGoogle Scholar
  214. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H. Design of a Novel Oral Fluoropyrimidine Carbamate, Capecitabine, which Generates 5-Fluorouracil Selectively in Tumors by Enzymes Concentrated in Human Liver and Tumor Tissue. Eur J Cancer 1998; 34:1274–1281PubMedGoogle Scholar
  215. Mohamedali KA, Guicherit OM, Kellems RE and Rudolph FB. The Highest Levels of Purine Catabolic Enzymes in Mice are Present in the Proximal Small Intestine. J Biol Chem 1993; 268:23728–23733PubMedGoogle Scholar
  216. Morgan ME, Chi S-C, Murakami K, Mitsuya H and Anderson BD. Central Nervous System Targeting of 2′,3′-Dideoxyinosine via Adenosine Deaminase-Activated 6-Halo-Dideoxypurine Prodrugs. Antimicrob Agents Chemother 1992; 36:2156–2165PubMedGoogle Scholar
  217. Morgan ME, Singhal D and Anderson BD. Quantitative Assessment of Blood-Brain Barrier Damage during Microdialysis. J Pharmacol Exp Ther 1996; 277:1167–1176PubMedGoogle Scholar
  218. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang Y-S, Hosoya K-I and Terasaki T. Rat Organic Anion Transporter 3 (OAT3) is Responsible for Brain-to-Blood Efflux of Homovanillic Acid at the Abluminal Membrane of Brain Capillary Endothelial Cells. J Cereb Blood Flow Metab 2003; 23:432–440PubMedGoogle Scholar
  219. Morikawa M, Inoue M and Tsuboi M. Substrate Specificity of Carboxylesterase from Several Animals. Chem Pharm Bull 1976; 24:1661–1664PubMedGoogle Scholar
  220. Moriwaki Y, Yamamoto T, Yamaguchi K, Takahashi S and Higashino K. Immunohistochemical Localization of Aldehyde and Xanthine Oxidase in Rat Tissues Using Polyclonal Antibodies. Histochem Cell Biol 1996; 105:71–79PubMedGoogle Scholar
  221. Moriwaki Y, Yamamoto T and Higashino K. Enzymes Involved in Purine Metabolism—A Review of Histochemical Localization and Functional Implications. Histol Histopathol 1999; 14:1321–40PubMedGoogle Scholar
  222. Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z and Hada T. Widespread Cellular Distribution of Aldehyde Oxidase in Human Tissues Found by Immunohistochemistry Staining. Histol Histopathol 2001; 16:745–753PubMedGoogle Scholar
  223. Mullen CA. Transfer of the Bacterial Gene for Cytosine Deaminase to Mammalian Cells Confers Lethal Sensitivity to 5-Fluorocytosine: A Negative Selection System. Proc Natl Acad Sci USA 1992; 89:33–37PubMedGoogle Scholar
  224. Murakami K, Shirasaka T, Yoshioka H, Kojima E, Aoki S, Ford H, Jr., Driscoll JS, Kelley JA and Mitsuya H. Escherichia Coli Mediated Biosynthesis and In Vitro Anti-HIV Activity of Lipophilic 6-Halo-2′,3′-Dideoxypurine Nucleosides J Med Chem 1991; 34:1606–1612PubMedGoogle Scholar
  225. Nafe C, Cao Y-J, Quinones A, Dobberstein K-U, Kramm CM and Rainov NG. Expression of Mutant Non-Cleavable Fas Ligand on Retrovirus Packaging Cells Causes Apoptosis of Immunocompetent Cells and Improves Prodrug Activation Gene Therapy in a Malignant Glioma Model. Life Sci 2003; 73:1847–1860PubMedGoogle Scholar
  226. Namane A, Gouyette C, Fillion M-P, Fillion G and Huynh-Dinh T. Improved Brain Delivery of AZT Using a Glycosyl Phosphotriester Prodrug. J Med Chem 1992; 35:3039–3044PubMedGoogle Scholar
  227. Neuwelt EA, Ed. Implications of the Blood-Brain Barrier and Its Manipulation Vol 1: Basic Science Aspects New York, Plenum Publishing Corp.; 1989. 403 pGoogle Scholar
  228. Newlands ES, Blackledge GRP, Slacki JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH and Gibson AC. Phase I Trial of Temozolomide (CCRG 81045:M&B 39831:NSC 362856). Br J Cancer 1992; 65:287–291PubMedGoogle Scholar
  229. Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournie-Zaluski MC and Roques BP. Inhibition of the Enkephalin-Metabolizing Enzymes by the First Systemically Active Mixed Inhibitor Prodrug RB 101 Induces Potent Analgesic Responses in Mice and Rats. J Pharmacol Exp Ther 1992; 261:181–190PubMedGoogle Scholar
  230. Nordstrom M, Abrahamsson T, Ervik M, Forshult E and Regardh CG. Central Nervous and Systemic Kinetics of Ramipril and Ramiprilat in the Conscious Dog. J Pharmacol Exp Ther 1993; 266:147–152PubMedGoogle Scholar
  231. O’Brien EM, Tipton KF, Strolin Benedetti M, Bonsignori A, Marrari P and Dostyert P. Is the Oxidation of Milacemide by Monoamine Oxidase a Major Factor in its Anticonvulsant Actions? Biochem Pharmacol 1991; 41:1731–1737PubMedGoogle Scholar
  232. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K-I, Otagiri M and Terasaki T. Role of Blood-Brain Barrier Organic Anion Transporter 3 (OAT3) in the Efflux of Indoxyl Sulfate, a Uremic Toxin: Its Involvement in Neurotransmitter Metabolite Clearance from the Brain. J Neurochem 2002; 83:57–66PubMedGoogle Scholar
  233. Ohtsuki S, Takizawa T, Takanaga H, Terasaki N, Kitazawa T, Sasaki M, Abe T, Hosoya KI and Terasaki T. In Vitro Study of the Functional Expression of Organic Anion Transporting Polypeptide 3 at Rat Choroid Plexus Epithelial Cells and its Involvement in the Cerebrospinal Fluid-to-Blood Transport of Estrone-3-Sulfate. Mol Pharm 2003; 63:532–537Google Scholar
  234. Oldendorf WH. Brain Uptake of Radiolabeled Amino Acids, Amines, and Hexoses after Arterial Injection. Am J Physiol 1971; 221:1629–1639PubMedGoogle Scholar
  235. Ouyang H, Borchardt RT, Siahaan TJ and Vander Velde D. Synthesis and Conformation Study of a Coumarinic Acid-Based Cyclic Prodrug of Opioid Peptide with Modified Sensitivity to Esterase-Catalyzed Bioconversion. J Pept Res 2002; 59:183–195PubMedGoogle Scholar
  236. Parang K, Knaus EE and Wiebe LI. Synthesis, In Vitro Anti-HIV Activity, and Biological Stability of 5′-O-Myristoyl Analogue Derivatives of 3′-Fluoro-2′,3′-Dideoxythymidine (FLT) as Potential Bifunctional Prodrugs of FLT. Nucleosides Nucleotides 1998a; 17:987–1008PubMedGoogle Scholar
  237. Parang K, Wiebe LI and Knaus EE. Pharmacokinetics and Tissue Distribution of (+)-3′-Azido-2′,3′-Dideoxy-5′-O-(2-Bromomyristoyl)thymidine, a Prodrug of 3′-Azido-2′,3′-Dideoxythymidine(AZT) in Mice. J Pharm Pharmacol 1998b; 50:989–996PubMedGoogle Scholar
  238. Parang K, Wiebe LI and Knaus EE. Synthesis, In Vitro Anti-Human Immunodeficiency Virus Structure-Activity Relationships and Biological Stability of 5′-O-Myristoyl Analog Derivatives of 3′-Azido-2′,3′-Dideoxythymidine (AZT) as Potential Prodrugs. Antiviral Chem Chemother 1998c; 9:311–323Google Scholar
  239. Parang K, Wiebe LI and Knaus EE. Novel Approaches for Designing 5′-O-Ester Prodrugs of 3′-Azido-2′3′-Dideoxythymidine (AZT). Curr Med Chem 2000; 7:995–1039PubMedGoogle Scholar
  240. Pardridge WM. Peptide Drug Delivery to the Brain New York, Raven Press; 1991. 357 pGoogle Scholar
  241. Pardridge WM. Brain Drug Delivery andBlood-Brain Barrier Transport. Drug Delivery 1993; 1:83–101Google Scholar
  242. Pardridge WM. Brain Drug Targeting: The Future of Brain Drug Development Cambridge, U.K., Cambridge University Press; 2001. 352 pGoogle Scholar
  243. Pardridge WM. Drug and Gene Delivery to the Brain: The Vascular Route. Neuron 2002; 36:555–558PubMedGoogle Scholar
  244. Pardridge WM, Boado RJ and Farrell CR. Brain-Type Glucose Transporter (GLUT-1) is Selectively Localized to the Blood-Brain Barrier. Studies with Quantitative Western Blotting and In Situ Hybridization. J Biol Chem 1990a; 265:18035–18040PubMedGoogle Scholar
  245. Pardridge WM, Triguero D and Buciak JL. β-Endorphin Chimeric Peptides: Transport through the Blood-Brain Barrier In Vivo and Cleavage of Disulfide Linkage by Brain. Endocrinology 1990b; 126:977–984PubMedCrossRefGoogle Scholar
  246. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Webb DSA, Hao Z, Mitsuya H, Johns DG and Broder S. Replication of Human Immunodeficiency Virus in Monocytes. J Exp Med 1989; 169:933–951PubMedGoogle Scholar
  247. Pizzo PA. Pediatric AIDS: Problems Within Patients. J Infect Dis 1990; 161:316–325PubMedGoogle Scholar
  248. Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M, Broder S, Yarchoan R, Brunetti A, Maha M, Nusinoff-Lehrman S and Poplack DG. Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV Infection. N Engl J Med 1988; 319:889–896PubMedCrossRefGoogle Scholar
  249. Pop E, Loftsson T and Bodor N. Solubilization and Stabilization of a Benzylpenicillin Chemical Delivery System by 2-Hydroxypropyl-β-Cyclodextrin. Pharm Res 1984; 8:1044–1049Google Scholar
  250. Prokai L, Ouyang X, Wu W and Bodor N. Chemical Delivery System to Transport a Puroglutamyl Peptide Amide to the Central Nervous System. J Amer Chem Soc 1994; 116:2643–2644Google Scholar
  251. Prokai L, Prokai-Tatrai K, Ouyang X, Kim H-S, Wu W-M, Zharikova A and Bodor N. Metabolism-Based Brain-Targeting System for a Thyrotropin-Releasing Hormone Analogue. J Med Chem 1999; 42:4563–4571PubMedGoogle Scholar
  252. Prokai L, Prokai-Tatrai K and Bodor N. Targeting Drugs to the Brain by Redox Chemical Delivery Systems. Med Res Rev 2000; 20:367–416PubMedGoogle Scholar
  253. Prokai-Tatrai K, Nguyen V, Zharikova AD, Braddy AC, Stevens J, S. M. and Prokai L. Prodrugs to Enhance Central Nervous System Effects of the TRH-like Peptide pGlu-Glu-Pro-NH2. Bioorg Med Chem Lett 2003; 13:1011–1014PubMedGoogle Scholar
  254. Pu AT, Robertson JM and Lawrence TS. Current Status of Radiation Sensitization by Fluoropyrimidines. Oncology (Huntingt) 1995; 9:707–714Google Scholar
  255. Quon CY, Mai K, Patil G and Stampfli HF. Species Differences in the Stereoselective Hydrolysis of Esmolol by Blood Esterases. Drug Metab Dispos 1988; 16:425–428PubMedGoogle Scholar
  256. Rainov NG. A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme. Hum Gene Ther 2000; 11:2389–2401PubMedGoogle Scholar
  257. Ram Z, Culver KW, Walbridge S, Blaese RM and Oldfield EH. In Situ Retroviral-Mediated Gene Transfer for the Treatment of Brain Tumours in Rats. Cancer Res 1993; 53:83–88PubMedGoogle Scholar
  258. Ranadive SA, Chen AX and Serajuddin ATM. Relative Lipophilicities and Structural-Pharmacological Considerations of Various Angiotensin-Converting Enzyme (ACE) Inhibitors. Pharm Res 1992; 9:1480–1486PubMedGoogle Scholar
  259. Rapoport SI. Blood-Brain Barrier in Physiology and Medicine New York, Raven Press; 1976. 316 pGoogle Scholar
  260. Rapoport SI, Ohno K and Pettigrew KD. Drug Entry into the Brain. Brain Res 1979; 172:354–359PubMedGoogle Scholar
  261. Raub TJ, Barsuhn CL, Williams LR, Decker DE, Sawada GA and Ho NFH. Use of a Biophysical-Kinetic Model to Understand the Roles of Protein Binding and Membrane Partitioning on Passive Diffusion of Highly Lipophilic Molecules across Cellular Barriers. J Drug Target 1993; 1:269–286PubMedGoogle Scholar
  262. Reese T and Karnovsky M. Fine Structural Localization of a Blood-Brain Barrier to Exogenous Peroxidase. J Cell Biol 1967; 34:207–217PubMedGoogle Scholar
  263. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO and Roux F. MRP1 Multidrug Resistance-Associated Protein and PGlycoprotein Expression in Rat Brain Microvessel Endothelial Cells. J Neurochem 1998; 71:705–715PubMedCrossRefGoogle Scholar
  264. Rehemtulla A, Hall DE, Stegman LD, Prasad U, Chen G, Bhojani MS, Chenevert TL and Ross BD. Molecular Imaging of Gene Expression and Efficacy following Adenoviral-Mediated Brain Tumor Gene Therapy. Mol Imaging 2002; 1:43–55PubMedGoogle Scholar
  265. Richter K, Kawashima E, Egger R and Kreil G. Biosynthesis of Thyrotropin-Releasing Hormone in the Skin of Xenopus Laevis: Partial Sequence of the Precursor Deduced from Cloned cDNA. EMBO J 1994; 3:617–621Google Scholar
  266. Roba J, Cavalier R, Cordi A, Gorissen H, Herin M, De Varebeke JP, Onkelinx C, Remacle M and Van Dorsser W. Milacemide. In: Meldrum BS, and Porter RH. New Anticonvulsant Drugs. London, J. Libbey & Co.; 1986:179–190Google Scholar
  267. Robinson PJ and Rapoport SI. Kinetics of Protein Binding Determine Rates of Uptake of Drugs by Brain. Am J Physiol 1986; 351:R1212–R1220Google Scholar
  268. Robinson PJ and Rapoport SI. Transport of Drugs. In: Bradbury MWB. Physiology and Pharmacology of the Blood-Brain Barrier. Berlin, Springer-Verlag; 1992:279–300Google Scholar
  269. Rooseboom M, Commandeur JNM and Vermeulen NPE. Enzyme-Catalyzed Activation of Anticancer Prodrugs. Pharmacol Rev 2004; 56:53–102PubMedGoogle Scholar
  270. Roques BP and Fournie-Zaluski M. Enkephalin Degrading Enzyme Inhibitors: A Physiological Way to New Analgesics and Psychoactive Agents. In: Rapaka RS, and Hawks RL. Opioid Peptides: Molecular, Pharmacology, Biosynthesis and Analysis; 1986:128–154Google Scholar
  271. Roques BP, Lucas-Soroca E, Chaillet P, Costentin J and Fournie-Zaluski MC. The Enkephalinase Inhibitor Thiorphan Shows Antinociceptive Activity in Mice. Nature (Lond) 1980; 288:286–288Google Scholar
  272. Rosowsky A, Abelson H, Beardsley G, Ensminger WD, Kufe DW, Steele G and Modest EJ. Pharmacological Studies on the Dibutyl and γ-Monobutyl Esters of Methotrexate in the Rhesus Monkey. Cancer Chemother Pharmacol 1982; 10:55–61PubMedGoogle Scholar
  273. Roth JS, McCully CM, Balis FM, Poplack DG and Kelley JA. 2′-β-Fluoro-2′,3′-Dideoxyadenosine, Lodenosine, in Rhesus Monkeys: Plasma and Cerebrospinal Fluid Pharmacokinetics and Urinary Disposition. Drug Metab Disp 1999; 27:1128–1132Google Scholar
  274. Rouleau A, Garbarg M, Ligneau X, Mantion C, Lavie P, Lecomte J-M, Krause M, Stark H, Schunack W and Schwartz J-C. Bioavailability, Antinociceptive and Antiinflammatory Properties of BP 2-94, A Histamine H3 Receptor Agonist Prodrug. J Pharmacol Exp Ther 1997; 281:1085–1094PubMedGoogle Scholar
  275. Rouquayrol M, Gaucher B, Greiner J, Aubertin A-M, Vierling P and Guedj R. Synthesis and Anti-HIV Activity of Glucose-Containing Prodrugs Derived from Saquinavir, Indinavir and Nelfinavir. Carbohydrate Res 2001; 336:161–180Google Scholar
  276. Russell JW and Klunk LJ. Comparative Pharmacokinetics of New Anti-HIV agents: 2′,3′-Dideoxyadenosine and 2′,3′-Dideoxyinosine. Biochem Pharmacol 1989; 38:1385–1388PubMedGoogle Scholar
  277. Saito Y, Buciak J, Yang J and Pardridge WM. Vector-Mediated Delivery of {sr1257#x007D;I-Labeled β-Amyloid Peptide A-β1-40 through the Blood-Brain Barrier and Binding to Alzheimer Disease Amyloid of the A-β1-40/Vector Complex. Proc Natl Acad Sci USA 1995; 92:10227–10231PubMedGoogle Scholar
  278. Saletu B, Grunberger J and Linzmayer L. Acute and Subacute Central Nervous System Effects of Milacemide in Elderly People: Double-Blind Placebo Controlled Quantitative Electroencephalography and Psychometric Investigations. Arch Gerentol Geriat 1986; 5:165–182Google Scholar
  279. Salituro FG, Tomlinson RC, Baron BM, Palfreyman MG, McDonald IA, Schmidt W, Wu H-Q, Guidetti P and Schwarcz R. Enzyme-Activated Antagonists of the Strychnine-Insensitive Glycine/NMDA Receptor. J Med Chem 1994; 37:334–336PubMedGoogle Scholar
  280. Samtani MN, Schwab M, Nathanielsz PW and Jusko WJ. Stabilization and HPLC Analysis of Beztamethasone Sodium Phosphate in Plasma. J Pharm Sci 2004; 93:726–732PubMedGoogle Scholar
  281. Sasaki S, Kanda T, Ishibashi N, Yamamoto F, Haradahira T, Okauchi T, Meda J, Suzuki K and Maeda M. 4,5,9,10-Tetrahydro-1,4-Ethanobenz [b]quinolizine as a Prodrug for its Quinolizinium Cation as a Ligand to the Open State of the TCP-Binding Site of NMDA Receptors. Bioorg Med Chem Lett 2001; 11:519–521PubMedGoogle Scholar
  282. Sawchuk RJ and Yang Z. Investigation of Distribution, Transport and Uptake of Anti-HIV Drugs to the Central Nervous System. Adv Drug Deliv Rev 1999; 39:5–31PubMedGoogle Scholar
  283. Schinkel AH and Jonker JW. Mammalian Drug Efflux Transporters of the ATP Binding Cassette (ABC) Family: An Overview. Adv Drug Deliv Rev 2003; 55:3–29PubMedGoogle Scholar
  284. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P. Disruption of the Mouse MDR1a P-Glycoprotein Gene Leads to a Deficiency in the Blood-Brain Barrier and to Increased Sensitivity to Drugs. Cell 1994; 77:491–502PubMedGoogle Scholar
  285. Schinkel AH, Wagenaar E, Mol CAAM and van Deemter L. P-Glycoprotein in the Blood-Brain Barrier of Mice Influences the Brain Penetration and Pharmacological Activity of Many Drugs. J Clin Invest 1996; 97:2517–2524PubMedCrossRefGoogle Scholar
  286. Schlienger N, Peyrottes S, Kassem T, Imbach J-L, Gosselin G, Aubertin A-M and Perigaud C. S-Acyl-2-Thioethyl Aryl Phosphotriester Derivatives as Mononucleotide Prodrugs. J Med Chem 2000; 43:4570–4574PubMedGoogle Scholar
  287. Schrader WP, West CA and Strominger NL. Localization of Adenosine Deaminase and Adenosine Deaminase Complexing Protein in Rabbit Brain. J Histochem Cytochem 1987; 35:443–451PubMedGoogle Scholar
  288. Schwartz BL, Hashtroudi S, Herting RL, Handerson H and Deutsch SI. Glycine Prodrug Facilitates Memory Retrieval in Humans. Neurology 1991; 41:1341–1343PubMedGoogle Scholar
  289. Seetharaman S, Barrand MA, Maskell L and Scheper RJ. Multidrug Resistance-Related Transport Proteins in Isolated Human Brain Microvessels and in Cells Cultured from these Isolates. J Neurochem 1998; 70:1151–1159PubMedCrossRefGoogle Scholar
  290. Semba J, Curzon G and Patsalos PN. Antiepileptic Drug Pharmacokinetics and Neuropharmacokinetics in Individual Rats by Repetitive Withdrawal of Blood and Cerebrospinal Fluid: Milacemide. Br J Pharmacol 1993; 108:1117–1124PubMedGoogle Scholar
  291. Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG and Barbier N. A Phase 1-2 Clinical Trial of Gene Therapy for Recurrent Glioblastoma Multiforme by Tumour Transduction with Herpes Simplex Thymidine Kinase Gene followed by Ganciclovir. Hum Gene Ther 1999; 10:2325–2335PubMedGoogle Scholar
  292. Shanmuganathan K, Koudriakova T, Nampalli S, Du J, Gallo JM, Schinazi RF and Chu CK. Enhanced Brain Delivery of an Anti-HIV Nucleoside 2′-F-ara-ddI by Xanthine Oxidase Mediated Biotransformation. J Med Chem 1994; 37:821–827PubMedGoogle Scholar
  293. Shashoua VE, Jacob JN, Ridge R, Campbell A and Baldessarini RJ. γ-Aminobutyric Acid Esters. 1. Synthesis, Brain Uptake, and Pharmacological Studies of Aliphatic and Steroid Esters of γ-Aminobutyric Acid. J Med Chem 1984; 27:659–664PubMedGoogle Scholar
  294. Sheha M, Al-Tayeb A, El-Sherief H and Farag H. New Carrier for Specific Delivery of Drugs to the Brain. Bioorg Med Chem 2003; 11:1865–1872PubMedGoogle Scholar
  295. Shek E. Chemical Delivery Systems and Prodrugs of Anticonvulsive Drugs. Adv Drug Delivery Rev 1994; 14:227–241Google Scholar
  296. Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach J-L and Mitsuya H. Comparative Analysis of Anti-Human Immunodeficiency Virus Type 1 Activities of Dideoxynucleoside Analogs in Resting and Activated Peripheral Blood Mononuclear Cells. Antimicrob Agents Chemother 1995; 39:2555–2559PubMedGoogle Scholar
  297. Shirasaka T, Murakami K, Ford H, Kelly JA, Yoshioka H, Kojima E, Aoki S, Broder S and Mitsuya H. Lipophilic Halogenated Congeners of 2′,3′-Dideoxypurine Nucleosides Active Against Human Immunodeficiency Virus In Vitro. Proc Natl Acad Sci USA 1990; 87:9426–9430PubMedGoogle Scholar
  298. Singhal D and Anderson BD. Optimization of the Local Inhibition of Intestinal Adenosine Deaminase (ADA) by Erythro-9-(2-Hydroxy-3-Nonyl)adenine: Enhanced Oral Delivery of an ADA-Activated Prodrug for Anti-HIV Therapy. J Pharm Sci 1998; 87:578–585PubMedGoogle Scholar
  299. Singhal D, Morgan ME and Anderson BD. The Role of Altered Metabolism in Dideoxynucleoside Pharmacokinetics. Studies of 2′-Fluoro-2′,3′-Dideoxyinosine and 2′-Fluoro-2′,3′-Dideoxyadenosine in Rats. Drug Metab Disp 1996; 24:1155–1161Google Scholar
  300. Singhal D, Morgan ME and Anderson BD. Role of Brain Tissue Localized Purine Metabolizing Enzymes in the Central Nervous System Delivery of Anti-HIV Agents 2′-β-Fluoro-2′,3′-Dideoxyinosine and 2′-β-Fluoro-2′,3′-Dideoxyadenosine in Rats. Pharm Res 1997; 14:786–792PubMedGoogle Scholar
  301. Singhal D, Ho NF and Anderson BD. Absorption and Intestinal Metabolism of Purine Dideoxynucleosides and an Adenosine Deaminase-Activated Prodrug of 2′,3′-Dideoxyinosine in the Mesenteric Vein Cannulated Rat Ileum. J Pharm Sci 1998; 87:569–577PubMedGoogle Scholar
  302. Smith QR. Drug Delivery to Brain and the Role of Carrier-Mediated Transport. In: Drewes LR, and Betz AL. Frontiers in Cerebral Vascular Biology: Transport and Its Regulation. New York, Plenum Press; 1993:83–100Google Scholar
  303. Solhonne B, Gros C, Pollard H and Schwartz JC. Major Localization of Aminopeptidase M in Rat Brain Microvessels. Neuroscience 1987; 22:225–232PubMedGoogle Scholar
  304. Somogyi G, Buchwald P, Nomi D, Prokai L and Bodor N. Targeted Drug Delivery to the Brain via Phosphonate Derivatives II. Anionic Chemical Delivery System for Zidovudine (AZT). Int J Pharm 1998; 166:27–35Google Scholar
  305. Somogyi G, Nishitani S, Nomi D, Buchwald P, Prokai L and Bodor N. Targeted Drug Delivery to the Brain via Phosphonate Derivatives. I. Design, Synthesis and Evaluation of an Anionic Chemical Delivery System for Testosterone. Int J Pharm 1997; 166:15–26Google Scholar
  306. Starnes MC and Cheng Y-C. Cellular Metabolism of 2′,3′-Dideoxycytidine, a Compound Active Against Human Immunodeficiency Virus In Vitro. J Biol Chem 1987; 262:988–991PubMedGoogle Scholar
  307. Stella VJ and Himmelstein KJ. Prodrugs and Site-Specific Delivery. J Med Chem 1980; 23:1275–1282PubMedGoogle Scholar
  308. Stella VJ and Himmelstein KJ. Critique of Prodrugs and Site Specific Delivery. In: Bundgaard H, Hansen AB, and Kofod H. Optimization of Drug Delivery (Alfred Benzon Symposium). Copenhagen, Munksgaard; 1982:134–155Google Scholar
  309. Stella V and Himmelstein KJ. Site-Specific Drug Delivery via Prodrugs. In: Bundgaard H. Design of Prodrugs. Amsterdam, Elsevier; 1985:177–198Google Scholar
  310. Sugiyama Y, Kusuhara H and Suzuki H. Kinetic and Biochemical Analysis of Carrier-Mediated Efflux of Drugs through the Blood-Brain and Blood-Cerebrospinal Fluid Barriers: Importance in the Drug Delivery to the Brain. J Control Release 1999; 62:179–86PubMedGoogle Scholar
  311. Sun H, Dai H, Shaik N and Elmquist WF. Drug Efflux Transporters in the CNS. Adv Drug Deliv Rev 2003; 55:83–105PubMedGoogle Scholar
  312. Sunderland A, Mellow A, Cohen R, Lawlor B, Jill J, Newhouse P, Cohen M and Murphy D. Acute Effects of High-Dose Thyrotropin Releasing Hormone Infusions in Alzheimer’s Disease. Psychopharmacology 1989; 98:403–407PubMedGoogle Scholar
  313. Takasawa K, Terasaki T, Suzuki H and Sugiyama Y. In Vivo Evidence for Carrier-Mediated Efflux Transport of 3′-Azido-3′-Deoxythymidine and 2′,3′-Dideoxyinosine across the Blood-Brain Barrier via a Probenecid-Sensitive Transport System. J Pharmacol Exp Ther 1997; 281:369–375PubMedGoogle Scholar
  314. Tamai I and Tsuji A. Drug Delivery through the Blood-Brain Barrier. Adv Drug Deliv Rev 1996; 19:401–424Google Scholar
  315. Tamai I and Tsuji A. Transporter-Mediated Permeation of Drugs across the Blood-Brain Barrier. J Pharm Sci 2000; 89:1371–1388PubMedGoogle Scholar
  316. Tan X, Boudinot FD, Chu CK, Egron D, Perigaud C, Gosselin G and Imbach J-L. Pharmacokinetics of bis(t-butyl-SATE)-AZTMP, a Bispivaloylthioethyl Prodrug for Intracellular Delivery of Zidovudine Monophosphate, in Mice. Antivir Chem Chemother 2000; 11:203–212PubMedGoogle Scholar
  317. Tapfer MK, Sebestyen L, Kurucz I, Horvath K, Szelenyi I and Bodor N. New Evidence for the Selective, Long-Lasting Central Effects of the Brain-Targeted Estradiol, Estredox. Pharmacol Biochem Behav 2004; 77:423–429PubMedGoogle Scholar
  318. Terada LS, Willingham IR, Rosandich ME, Leff JA, Kindt GW and Repine JE. Generation of Superoxide Anion by Brain Endothelial Cell Xanthine Oxidase. J Cell Physiol 1991; 148:191–196PubMedGoogle Scholar
  319. Tomlinson E. Theory and Practice of Site-Specific Drug Delivery. Adv Drug Del Rev 1987; 1:87–164Google Scholar
  320. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H and Sugiyama Y. A Physiologically Based Pharmacokinetic Analysis of Capecitabine, a Triple Prodrug of 5-FU in Humans: The Mechanism for Tumor-Selective Accumulation of 5-FU. Pharm Res 2001; 18:1190–1202PubMedGoogle Scholar
  321. Tsuzuki N, Hama T, Kawada M, Hasui A, Konishi R, Shiwa S, Ochi Y, Futaki S and Kitagawa K. Adamantane as a Brain-Directed Drug Carrier for Poorly Absorbed Drug. 2. AZT Derivatives Conjugated with the 1-Adamantane Moiety. J Pharm Sci 1994; 83:481–484PubMedGoogle Scholar
  322. Tuntland T, Ravasco RJ, Al-Habet S and Unadkat JD. Active Efflux of Zidovudine and 2′,3′-Dideoxyinosine out of the Cerebrospinal Fluid when Administered Alone and in Combination to the Macaca nemestrina. Pharm Res 1994; 11:312–317PubMedGoogle Scholar
  323. Turner AJ, Hooper NM and Kenny AJ. Metabolism of Neuropeptides. In: Kenny AJ, and Turner AJ. Mammalian Ectoenzymes Amsterdam, Elsevier; 1987:221–241Google Scholar
  324. Van der Weyden MB and Kelley WN. Human Adenosine Deaminase. Distribution and Properties. J Biol Chem 1976; 251:5448–5456PubMedGoogle Scholar
  325. Van Dorsser W, Barris D, Cordi A and Roba J. Anticonvulsant Activity of Milacemide. Arch Int Pharmacodyn 1983; 266:239–249PubMedGoogle Scholar
  326. Van Hoof VO, Deng JT and De Broe ME. How Do Plasma Membranes Reach the Circulation? Clin Chim Acta 1997; 266:23–31PubMedGoogle Scholar
  327. Varasi M, Della Torre A, Heidempergher F, Pevarello P, Speciale C, guidetti P, Wells DR and Schwarcz R. Derivatives of Kynurenine as Inhibitors of Rat Brain Kynurenine Aminotransferase. Eur J Med Chem 1996; 31:11–21Google Scholar
  328. Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y and Endou H. Rat Multispecific Organic Anion Transporter 1 (rOAT1) Transports Zidovudine, Acyclovir, and Other Antiviral Nucleoside Analogs. J Pharmacol Exp Ther 2000; 294:844–849PubMedGoogle Scholar
  329. Wade LA and Katzman R. Synthetic Amino Acids and the Nature of L-Dopa Transport at the Blood-Brain Barrier. J Neurochem 1975; 25:837–842PubMedGoogle Scholar
  330. Wang H. Brain Delivery of Nipecotic Acid by the Administration of its Ester Prodrug via the Nasal Route. College of Pharmacy. Lexington, KY, University of Kentucky; 2003:172Google Scholar
  331. Wang H, Hussain AA and Wedlund PJ. Nipecotic Acid: Systemic Availability and Brain Delivery After Nasal Administration of Nipecotic Acid and n-Butyl Nipecotate to Rats. Pharm Res 2005; 22:556–562PubMedGoogle Scholar
  332. Wang Y and Sawchuk RJ. Zidovudine Transport in the Rabbit Brain during Intravenous and Intracerebroventricular Infusion. J Pharm Sci 1995; 84:871–876PubMedGoogle Scholar
  333. Wang Y, Wei Y and Sawchuk RJ. Zidovudine Transport Within the Rabbit Brain during Intracerebroventricular Administration and the Effect of Probenecid. J Pharm Sci 1995; 86:1484–1490Google Scholar
  334. Wang ZH, Samuels S, Gama Sosa MA and Kolodny EH. 5-Fluorocytosine-Mediated Apoptosis and DNA Damage in Glioma Cells Engineered to Express Cytosine Deaminase and their Enhancement with Interferon. J Neurooncol 1998; 36:219–229PubMedGoogle Scholar
  335. Wang B, Nimkar K, Wang W, Zhang H, Shan D, Gudmundsson O, Gangwar S, Siahaan T and Borchardt RT. Synthesis and Evaluation of the Physicochemical Properties of Esterase-Sensitive Cyclic Prodrugs of Opioid Peptides Using Coumarinic Acid and Phenylpropionic Acid Linkers. J Pept Res 1999; 53:370–382PubMedGoogle Scholar
  336. Wang ML, Yung WK, Royce ME, Schomer DF and Theriault RL. Capecitabine for 5-Fluorouracil-Resistant Brain Metastases from Breast Cancer. Am J Clin Oncol 2001; 24:421–424PubMedGoogle Scholar
  337. Wang WJ, Tai C-K, Kasahara N and Chen TC. Highly Efficient and Tumor-Restricted Gene Transfer to Malignant Gliomas by Replication-Competent Retroviral Vectors. Hum Gene Ther 2003; 14:117–127PubMedGoogle Scholar
  338. Wen Y-D, Remmel RP, Pham PT, Vince R and Zimmerman CL. Comparative Brain Exposure to (-)-Carbovir after (-)-Carbovir or (-)-6-Aminocarbovir Intravenous Infusion in Rats. Pharm Res 1995; 12:911–915PubMedGoogle Scholar
  339. Witt KA, Huber JD, Egleton RD, Roberts MJ, Bentley MD, Guo L, Wei H, Yamamura HI and Davis TP. Pharmacodynamic and Pharmacokinetic Characterization of Poly(ethylene glycol) Conjugation to Met-Enkephalin Analog [D-Pen2, D-Pen5]-Enkephalin (DPDPE). J Pharmacol Exp Ther 2001; 298:848–856PubMedGoogle Scholar
  340. Wong SL, Hedaya MA and Sawchuk RJ. Competitive Inhibition of Zidovudine Clearance by Probenecid during Continuous Coadministration. Pharm Res 1992; 9:228–235PubMedGoogle Scholar
  341. Wu H-Q, Lee S-C, Scharfman HE and Schwarcz R. L-4-Chlorokynurenine Attenuates Kainate-Induced Seizures and Lesions in the Rat. Exp Neurol 2002; 177:222–232PubMedGoogle Scholar
  342. Xiang T-X and Anderson BD. The Relationship between Permeant Size and Permeability in Lipid Bilayer Membranes. J Membr Biol 1994; 140:111–121PubMedGoogle Scholar
  343. Xiang T-X and Anderson BD. Influence of Chain Ordering on the Selectivity of Dipalmitoylphosphatidylcholine Bilayer Membranes for Permeant Size and Shape. Biophys J 1998; 75:2658–2671PubMedCrossRefGoogle Scholar
  344. Yang JZ, Chen W and Borchardt RT. In Vitro Stability and In Vivo Pharmacokinetic Studies of a Model Opioid Peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its Cyclic Prodrugs. J Pharmacol Exp Ther 2002; 303:840–848PubMedGoogle Scholar
  345. Yarbrough G. Thyrotropin Releasing Hormone and CNS Cholinergic Neurons. Life Sci 1983; 33:111–118PubMedGoogle Scholar
  346. Yoshikawa T, Sakaeda T, Sugawara T, Hirano K and Stella VJ. A Novel Chemical Delivery System for Brain Targeting. Adv Drug Del Rev 1999; 36:255–275Google Scholar
  347. Yu PH and Davis BA. Some Pharmacological Implications of MAO-Mediated Deamination of Branched Aliphatic Amines: 2-Propyl-1-Aminopentane and N-(2-Propylpentyl)glycinamide as Valproic Acid Precursors. J Neurol Trans Suppl 1990; 32:89–92Google Scholar
  348. Yu PH and Davis BA. Simultaneous Delivery of Valproic Acid and Glycine to the Brain. Deamination of 2-Propylpentylglycinamide by Monoamine Oxidase B. Mol Chem Neuropath 1991; 15:37–49CrossRefGoogle Scholar
  349. Yu PH, Davis BA, Boulton AA and Zuo DM. Deamination of Aliphatic Amines by Type B Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase; Pharmacological Implications. J Neural Transm Suppl 1994; 41:397–406PubMedGoogle Scholar
  350. Zhang Y, Han H, Elmquist WF and Miller DW. Expression of Various Multidrug Resistance-Associated Protein (MRP) Homologues in Brain Microvessel Endothelial Cells. Brain Res 2000; 876:148–153PubMedGoogle Scholar
  351. Zielke CL and Suelter CH. Purine, Purine Nucleoside, and Purine Nucleotide Aminohydrolases. In: Boyer PD. The Enzymes. London, Academic; 1971:47–78Google Scholar
  352. Zlokovic BV. Cerebrovascular Permeability to Peptides: Manipulations of Transport Systems at the Blood-Brain Barrier. Pharm Res 1995; 12:1395–1406PubMedGoogle Scholar
  353. Zlokovic BV, Lipovac MN, Begley DJ, Davson H and Rakic L. Slow Penetration of Thyrotropin-Releasing Hormone across the Blood-Brain Barrier of an In Situ Perfused Guinea Pig Brain. J Neurochem 1988; 51:252–257PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Bradley D. Anderson
    • 1
  1. 1.Department of Pharmaceutical Sciences College of PharmacyUniversity of KentuckyLexington

Personalised recommendations